Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Benjamin Fourneaux, Aurélien Bourdon, Bérengère Dadone, Carlo Lucchesi, Scott R. Daigle, Elodie Richard, Audrey Laroche-Clary, François Le Loarer, Antoine Italiano

ABSTRACT

BACKGROUND: Leiomyosarcoma (LMS) is one of the most frequent soft tissue sarcoma subtypes and is characterized by a consistent deregulation of the PI3K/mTOR pathway. Cancer stem cells (CSCs) have been poorly studied in soft tissue sarcomas. In this study, we aimed to evaluate the association between CSCs, the outcome of LMS patients, and the resistance to PI3K/mTOR pathway inhibition. METHODS: We investigated the relationships between aldehyde dehydrogenase 1 (ALDH1) expression, a cancer stem cell marker, and the outcome of LMS patients in two independent cohorts. We assessed the impact of CSCs in resistance to PI3K/mTOR pathway inhibition using LMS cell lines, a xenograft mouse model, and human tumor samples. RESULTS: We found that enhanced ALDH1 activity is a hallmark of LMS stem cells and is an independent prognostic factor. We also identified that secondary resistance to PI3K/mTOR pathway inhibition was associated with the expansion of LMS CSCs. Interestingly, we found that EZH2 inhibition, a catalytic component of polycomb repressive complex which plays a critical role in stem cell maintenance, restored sensitivity to PI3K/mTOR pathway inhibition. Importantly, we confirmed the clinical relevance of our findings by analyzing tumor samples from patients who showed secondary resistance after treatment with a PI3Kα inhibitor. CONCLUSIONS: Altogether, our findings suggest that CSCs have a strong impact on the outcome of patients with LMS and that combining PI3K/mTOR and EZH2 inhibitors may represent a promising strategy in this setting. More... »

PAGES

11

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13045-018-0694-1

DOI

http://dx.doi.org/10.1186/s13045-018-0694-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1111658385

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30683135


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Institut Bergoni\u00e9", 
          "id": "https://www.grid.ac/institutes/grid.476460.7", 
          "name": [
            "Universit\u00e9 de Bordeaux, Bordeaux, France", 
            "Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) U1218, Institut Bergoni\u00e9, 229 Cours de l\u2019Argonne, 33000, Bordeaux, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fourneaux", 
        "givenName": "Benjamin", 
        "id": "sg:person.0622243065.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0622243065.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Bergoni\u00e9", 
          "id": "https://www.grid.ac/institutes/grid.476460.7", 
          "name": [
            "Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) U1218, Institut Bergoni\u00e9, 229 Cours de l\u2019Argonne, 33000, Bordeaux, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bourdon", 
        "givenName": "Aur\u00e9lien", 
        "id": "sg:person.011230420521.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011230420521.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier Universitaire de Nice", 
          "id": "https://www.grid.ac/institutes/grid.410528.a", 
          "name": [
            "Department of Pathology, Nice University Hospital, Nice, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dadone", 
        "givenName": "B\u00e9reng\u00e8re", 
        "id": "sg:person.0722277402.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722277402.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Bergoni\u00e9", 
          "id": "https://www.grid.ac/institutes/grid.476460.7", 
          "name": [
            "Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) U1218, Institut Bergoni\u00e9, 229 Cours de l\u2019Argonne, 33000, Bordeaux, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lucchesi", 
        "givenName": "Carlo", 
        "id": "sg:person.01122200553.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122200553.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Epizyme (United States)", 
          "id": "https://www.grid.ac/institutes/grid.459523.c", 
          "name": [
            "Epizyme, Inc., Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Daigle", 
        "givenName": "Scott R.", 
        "id": "sg:person.01225706254.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225706254.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Bergoni\u00e9", 
          "id": "https://www.grid.ac/institutes/grid.476460.7", 
          "name": [
            "Universit\u00e9 de Bordeaux, Bordeaux, France", 
            "Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) U1218, Institut Bergoni\u00e9, 229 Cours de l\u2019Argonne, 33000, Bordeaux, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Richard", 
        "givenName": "Elodie", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Bergoni\u00e9", 
          "id": "https://www.grid.ac/institutes/grid.476460.7", 
          "name": [
            "Universit\u00e9 de Bordeaux, Bordeaux, France", 
            "Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) U1218, Institut Bergoni\u00e9, 229 Cours de l\u2019Argonne, 33000, Bordeaux, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Laroche-Clary", 
        "givenName": "Audrey", 
        "id": "sg:person.01002754123.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002754123.75"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Bergoni\u00e9", 
          "id": "https://www.grid.ac/institutes/grid.476460.7", 
          "name": [
            "Department of Medical Oncology, Institut Bergoni\u00e9, Bordeaux, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Le Loarer", 
        "givenName": "Fran\u00e7ois", 
        "id": "sg:person.01136751455.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136751455.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Bergoni\u00e9", 
          "id": "https://www.grid.ac/institutes/grid.476460.7", 
          "name": [
            "Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) U1218, Institut Bergoni\u00e9, 229 Cours de l\u2019Argonne, 33000, Bordeaux, France", 
            "Department of Medical Oncology, Institut Bergoni\u00e9, Bordeaux, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Italiano", 
        "givenName": "Antoine", 
        "id": "sg:person.01076406503.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01076406503.14"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1128/mcb.25.12.5084-5094.2005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006503177"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.18632/oncotarget.13987", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013042701"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/cddis.2011.84", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017623706", 
          "https://doi.org/10.1038/cddis.2011.84"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.stemcr.2015.12.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017860243"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-12-2970", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019753800"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.cancergencyto.2005.01.011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021444952"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/gcc.22318", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022761561"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.18632/oncotarget.6920", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030454788"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature04733", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038720785", 
          "https://doi.org/10.1038/nature04733"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature04733", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038720785", 
          "https://doi.org/10.1038/nature04733"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature04733", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038720785", 
          "https://doi.org/10.1038/nature04733"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/sciadv.1500447", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039074699"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jcp.25179", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041591559"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm1560", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043717288", 
          "https://doi.org/10.1038/nm1560"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.stem.2007.08.014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045510569"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1586/era.09.184", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046725650"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.cbi.2011.10.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049528776"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.25331", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051383727"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.25331", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051383727"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/mcb.21.13.4330-4336.2001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051446414"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.semcancer.2014.06.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053629465"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-16-2149", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083862086"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/widm.1219", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091490501"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.cell.2017.10.014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092501934"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(18)30145-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103197837"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(18)30145-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103197837"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(18)30145-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103197837"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: Leiomyosarcoma (LMS) is one of the most frequent soft tissue sarcoma subtypes and is characterized by a consistent deregulation of the PI3K/mTOR pathway. Cancer stem cells (CSCs) have been poorly studied in soft tissue sarcomas. In this study, we aimed to evaluate the association between CSCs, the outcome of LMS patients, and the resistance to PI3K/mTOR pathway inhibition.\nMETHODS: We investigated the relationships between aldehyde dehydrogenase 1 (ALDH1) expression, a cancer stem cell marker, and the outcome of LMS patients in two independent cohorts. We assessed the impact of CSCs in resistance to PI3K/mTOR pathway inhibition using LMS cell lines, a xenograft mouse model, and human tumor samples.\nRESULTS: We found that enhanced ALDH1 activity is a hallmark of LMS stem cells and is an independent prognostic factor. We also identified that secondary resistance to PI3K/mTOR pathway inhibition was associated with the expansion of LMS CSCs. Interestingly, we found that EZH2 inhibition, a catalytic component of polycomb repressive complex which plays a critical role in stem cell maintenance, restored sensitivity to PI3K/mTOR pathway inhibition. Importantly, we confirmed the clinical relevance of our findings by analyzing tumor samples from patients who showed secondary resistance after treatment with a PI3K\u03b1 inhibitor.\nCONCLUSIONS: Altogether, our findings suggest that CSCs have a strong impact on the outcome of patients with LMS and that combining PI3K/mTOR and EZH2 inhibitors may represent a promising strategy in this setting.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s13045-018-0694-1", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1039771", 
        "issn": [
          "1756-8722"
        ], 
        "name": "Journal of Hematology & Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "12"
      }
    ], 
    "name": "Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition", 
    "pagination": "11", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "6542f5edd9e15c13f13fcbe8a082d41deeacddea41e6f9487c5ba8e2522083f2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30683135"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101468937"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13045-018-0694-1"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1111658385"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13045-018-0694-1", 
      "https://app.dimensions.ai/details/publication/pub.1111658385"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T08:58", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000326_0000000326/records_68472_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs13045-018-0694-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13045-018-0694-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13045-018-0694-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13045-018-0694-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13045-018-0694-1'


 

This table displays all metadata directly associated to this object as RDF triples.

200 TRIPLES      21 PREDICATES      51 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13045-018-0694-1 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Na79315dfdc7142bfbe91890df387ab6b
4 schema:citation sg:pub.10.1038/cddis.2011.84
5 sg:pub.10.1038/nature04733
6 sg:pub.10.1038/nm1560
7 https://doi.org/10.1002/gcc.22318
8 https://doi.org/10.1002/ijc.25331
9 https://doi.org/10.1002/jcp.25179
10 https://doi.org/10.1002/widm.1219
11 https://doi.org/10.1016/j.cancergencyto.2005.01.011
12 https://doi.org/10.1016/j.cbi.2011.10.007
13 https://doi.org/10.1016/j.cell.2017.10.014
14 https://doi.org/10.1016/j.semcancer.2014.06.004
15 https://doi.org/10.1016/j.stem.2007.08.014
16 https://doi.org/10.1016/j.stemcr.2015.12.004
17 https://doi.org/10.1016/s1470-2045(18)30145-1
18 https://doi.org/10.1126/sciadv.1500447
19 https://doi.org/10.1128/mcb.21.13.4330-4336.2001
20 https://doi.org/10.1128/mcb.25.12.5084-5094.2005
21 https://doi.org/10.1158/1078-0432.ccr-12-2970
22 https://doi.org/10.1158/1078-0432.ccr-16-2149
23 https://doi.org/10.1586/era.09.184
24 https://doi.org/10.18632/oncotarget.13987
25 https://doi.org/10.18632/oncotarget.6920
26 schema:datePublished 2019-12
27 schema:datePublishedReg 2019-12-01
28 schema:description BACKGROUND: Leiomyosarcoma (LMS) is one of the most frequent soft tissue sarcoma subtypes and is characterized by a consistent deregulation of the PI3K/mTOR pathway. Cancer stem cells (CSCs) have been poorly studied in soft tissue sarcomas. In this study, we aimed to evaluate the association between CSCs, the outcome of LMS patients, and the resistance to PI3K/mTOR pathway inhibition. METHODS: We investigated the relationships between aldehyde dehydrogenase 1 (ALDH1) expression, a cancer stem cell marker, and the outcome of LMS patients in two independent cohorts. We assessed the impact of CSCs in resistance to PI3K/mTOR pathway inhibition using LMS cell lines, a xenograft mouse model, and human tumor samples. RESULTS: We found that enhanced ALDH1 activity is a hallmark of LMS stem cells and is an independent prognostic factor. We also identified that secondary resistance to PI3K/mTOR pathway inhibition was associated with the expansion of LMS CSCs. Interestingly, we found that EZH2 inhibition, a catalytic component of polycomb repressive complex which plays a critical role in stem cell maintenance, restored sensitivity to PI3K/mTOR pathway inhibition. Importantly, we confirmed the clinical relevance of our findings by analyzing tumor samples from patients who showed secondary resistance after treatment with a PI3Kα inhibitor. CONCLUSIONS: Altogether, our findings suggest that CSCs have a strong impact on the outcome of patients with LMS and that combining PI3K/mTOR and EZH2 inhibitors may represent a promising strategy in this setting.
29 schema:genre research_article
30 schema:inLanguage en
31 schema:isAccessibleForFree true
32 schema:isPartOf N252042d19d3c4705b683d52ee043dc3b
33 N4b55dc4c6d9c4bd2bb5b20cd2ced76a4
34 sg:journal.1039771
35 schema:name Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition
36 schema:pagination 11
37 schema:productId N541f3cb1f69c4051b2e3a681a6dbbbd7
38 N64916931a8ba44e1baef2fbbe51783b7
39 Na6ac0c0fc6e44761b7de5baf4fbc625d
40 Naec1f07ffefa419f91370ff98e221288
41 Ncd8059659945492f857214efe0d5f619
42 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111658385
43 https://doi.org/10.1186/s13045-018-0694-1
44 schema:sdDatePublished 2019-04-11T08:58
45 schema:sdLicense https://scigraph.springernature.com/explorer/license/
46 schema:sdPublisher N1c363bc7406f44fe91376b817d19c13c
47 schema:url https://link.springer.com/10.1186%2Fs13045-018-0694-1
48 sgo:license sg:explorer/license/
49 sgo:sdDataset articles
50 rdf:type schema:ScholarlyArticle
51 N0a1abe72e0f0423cae677634351558a5 rdf:first sg:person.01076406503.14
52 rdf:rest rdf:nil
53 N129cda07de6e48d39c3e869fd31d2b4c rdf:first N84de1494f1814583addbe5fd68f97a93
54 rdf:rest Nd1a849cbf3614c27818e4e51262b5083
55 N1c363bc7406f44fe91376b817d19c13c schema:name Springer Nature - SN SciGraph project
56 rdf:type schema:Organization
57 N252042d19d3c4705b683d52ee043dc3b schema:volumeNumber 12
58 rdf:type schema:PublicationVolume
59 N4b55dc4c6d9c4bd2bb5b20cd2ced76a4 schema:issueNumber 1
60 rdf:type schema:PublicationIssue
61 N541f3cb1f69c4051b2e3a681a6dbbbd7 schema:name readcube_id
62 schema:value 6542f5edd9e15c13f13fcbe8a082d41deeacddea41e6f9487c5ba8e2522083f2
63 rdf:type schema:PropertyValue
64 N556050f4be254a70a8705013eecde548 rdf:first sg:person.01225706254.79
65 rdf:rest N129cda07de6e48d39c3e869fd31d2b4c
66 N5dc994889be44d33843355067a0af372 rdf:first sg:person.011230420521.34
67 rdf:rest Nd02dc582c5eb463aa6bbffed02722be6
68 N64916931a8ba44e1baef2fbbe51783b7 schema:name doi
69 schema:value 10.1186/s13045-018-0694-1
70 rdf:type schema:PropertyValue
71 N849098b1b21c42eca56421e1d6d1d049 rdf:first sg:person.01136751455.54
72 rdf:rest N0a1abe72e0f0423cae677634351558a5
73 N84de1494f1814583addbe5fd68f97a93 schema:affiliation https://www.grid.ac/institutes/grid.476460.7
74 schema:familyName Richard
75 schema:givenName Elodie
76 rdf:type schema:Person
77 Na6ac0c0fc6e44761b7de5baf4fbc625d schema:name nlm_unique_id
78 schema:value 101468937
79 rdf:type schema:PropertyValue
80 Na79315dfdc7142bfbe91890df387ab6b rdf:first sg:person.0622243065.81
81 rdf:rest N5dc994889be44d33843355067a0af372
82 Nad4568570a6441e2ac85130ba3b8496e rdf:first sg:person.01122200553.33
83 rdf:rest N556050f4be254a70a8705013eecde548
84 Naec1f07ffefa419f91370ff98e221288 schema:name pubmed_id
85 schema:value 30683135
86 rdf:type schema:PropertyValue
87 Ncd8059659945492f857214efe0d5f619 schema:name dimensions_id
88 schema:value pub.1111658385
89 rdf:type schema:PropertyValue
90 Nd02dc582c5eb463aa6bbffed02722be6 rdf:first sg:person.0722277402.01
91 rdf:rest Nad4568570a6441e2ac85130ba3b8496e
92 Nd1a849cbf3614c27818e4e51262b5083 rdf:first sg:person.01002754123.75
93 rdf:rest N849098b1b21c42eca56421e1d6d1d049
94 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
95 schema:name Medical and Health Sciences
96 rdf:type schema:DefinedTerm
97 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
98 schema:name Oncology and Carcinogenesis
99 rdf:type schema:DefinedTerm
100 sg:journal.1039771 schema:issn 1756-8722
101 schema:name Journal of Hematology & Oncology
102 rdf:type schema:Periodical
103 sg:person.01002754123.75 schema:affiliation https://www.grid.ac/institutes/grid.476460.7
104 schema:familyName Laroche-Clary
105 schema:givenName Audrey
106 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002754123.75
107 rdf:type schema:Person
108 sg:person.01076406503.14 schema:affiliation https://www.grid.ac/institutes/grid.476460.7
109 schema:familyName Italiano
110 schema:givenName Antoine
111 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01076406503.14
112 rdf:type schema:Person
113 sg:person.01122200553.33 schema:affiliation https://www.grid.ac/institutes/grid.476460.7
114 schema:familyName Lucchesi
115 schema:givenName Carlo
116 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122200553.33
117 rdf:type schema:Person
118 sg:person.011230420521.34 schema:affiliation https://www.grid.ac/institutes/grid.476460.7
119 schema:familyName Bourdon
120 schema:givenName Aurélien
121 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011230420521.34
122 rdf:type schema:Person
123 sg:person.01136751455.54 schema:affiliation https://www.grid.ac/institutes/grid.476460.7
124 schema:familyName Le Loarer
125 schema:givenName François
126 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136751455.54
127 rdf:type schema:Person
128 sg:person.01225706254.79 schema:affiliation https://www.grid.ac/institutes/grid.459523.c
129 schema:familyName Daigle
130 schema:givenName Scott R.
131 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225706254.79
132 rdf:type schema:Person
133 sg:person.0622243065.81 schema:affiliation https://www.grid.ac/institutes/grid.476460.7
134 schema:familyName Fourneaux
135 schema:givenName Benjamin
136 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0622243065.81
137 rdf:type schema:Person
138 sg:person.0722277402.01 schema:affiliation https://www.grid.ac/institutes/grid.410528.a
139 schema:familyName Dadone
140 schema:givenName Bérengère
141 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722277402.01
142 rdf:type schema:Person
143 sg:pub.10.1038/cddis.2011.84 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017623706
144 https://doi.org/10.1038/cddis.2011.84
145 rdf:type schema:CreativeWork
146 sg:pub.10.1038/nature04733 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038720785
147 https://doi.org/10.1038/nature04733
148 rdf:type schema:CreativeWork
149 sg:pub.10.1038/nm1560 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043717288
150 https://doi.org/10.1038/nm1560
151 rdf:type schema:CreativeWork
152 https://doi.org/10.1002/gcc.22318 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022761561
153 rdf:type schema:CreativeWork
154 https://doi.org/10.1002/ijc.25331 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051383727
155 rdf:type schema:CreativeWork
156 https://doi.org/10.1002/jcp.25179 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041591559
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1002/widm.1219 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091490501
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1016/j.cancergencyto.2005.01.011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021444952
161 rdf:type schema:CreativeWork
162 https://doi.org/10.1016/j.cbi.2011.10.007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049528776
163 rdf:type schema:CreativeWork
164 https://doi.org/10.1016/j.cell.2017.10.014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092501934
165 rdf:type schema:CreativeWork
166 https://doi.org/10.1016/j.semcancer.2014.06.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053629465
167 rdf:type schema:CreativeWork
168 https://doi.org/10.1016/j.stem.2007.08.014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045510569
169 rdf:type schema:CreativeWork
170 https://doi.org/10.1016/j.stemcr.2015.12.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017860243
171 rdf:type schema:CreativeWork
172 https://doi.org/10.1016/s1470-2045(18)30145-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103197837
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1126/sciadv.1500447 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039074699
175 rdf:type schema:CreativeWork
176 https://doi.org/10.1128/mcb.21.13.4330-4336.2001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051446414
177 rdf:type schema:CreativeWork
178 https://doi.org/10.1128/mcb.25.12.5084-5094.2005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006503177
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1158/1078-0432.ccr-12-2970 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019753800
181 rdf:type schema:CreativeWork
182 https://doi.org/10.1158/1078-0432.ccr-16-2149 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083862086
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1586/era.09.184 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046725650
185 rdf:type schema:CreativeWork
186 https://doi.org/10.18632/oncotarget.13987 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013042701
187 rdf:type schema:CreativeWork
188 https://doi.org/10.18632/oncotarget.6920 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030454788
189 rdf:type schema:CreativeWork
190 https://www.grid.ac/institutes/grid.410528.a schema:alternateName Centre Hospitalier Universitaire de Nice
191 schema:name Department of Pathology, Nice University Hospital, Nice, France
192 rdf:type schema:Organization
193 https://www.grid.ac/institutes/grid.459523.c schema:alternateName Epizyme (United States)
194 schema:name Epizyme, Inc., Cambridge, MA, USA
195 rdf:type schema:Organization
196 https://www.grid.ac/institutes/grid.476460.7 schema:alternateName Institut Bergonié
197 schema:name Department of Medical Oncology, Institut Bergonié, Bordeaux, France
198 Institut National de la Santé et de la Recherche Medicale (INSERM) U1218, Institut Bergonié, 229 Cours de l’Argonne, 33000, Bordeaux, France
199 Université de Bordeaux, Bordeaux, France
200 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...